- Home
- NCT vs ASMB Comparison
NCT vs ASMB Comparison
Compare NCT & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCT
- ASMB
- Stock Information
- Founded
- NCT 2011
- ASMB 2005
- Country
- NCT Hong Kong
- ASMB United States
- Employees
- NCT N/A
- ASMB N/A
- Industry
- NCT
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- NCT
- ASMB Health Care
- Exchange
- NCT NYSE
- ASMB Nasdaq
- Market Cap
- NCT 114.7M
- ASMB 130.2M
- IPO Year
- NCT 2025
- ASMB 2010
- Fundamental
- Price
- NCT $3.79
- ASMB $17.39
- Analyst Decision
- NCT
- ASMB Strong Buy
- Analyst Count
- NCT 0
- ASMB 3
- Target Price
- NCT N/A
- ASMB $33.00
- AVG Volume (30 Days)
- NCT 35.3K
- ASMB 22.2K
- Earning Date
- NCT 01-01-0001
- ASMB 08-07-2025
- Dividend Yield
- NCT N/A
- ASMB N/A
- EPS Growth
- NCT N/A
- ASMB N/A
- EPS
- NCT 0.13
- ASMB N/A
- Revenue
- NCT $25,526,936.00
- ASMB $32,154,000.00
- Revenue This Year
- NCT N/A
- ASMB $0.04
- Revenue Next Year
- NCT N/A
- ASMB N/A
- P/E Ratio
- NCT $25.48
- ASMB N/A
- Revenue Growth
- NCT N/A
- ASMB 148.33
- 52 Week Low
- NCT $3.05
- ASMB $7.75
- 52 Week High
- NCT $8.76
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- NCT N/A
- ASMB 71.41
- Support Level
- NCT N/A
- ASMB $15.84
- Resistance Level
- NCT N/A
- ASMB $17.60
- Average True Range (ATR)
- NCT 0.00
- ASMB 0.93
- MACD
- NCT 0.00
- ASMB 0.01
- Stochastic Oscillator
- NCT 0.00
- ASMB 88.04
About NCT INTERCONT (CAYMAN) LIMITED
Intercont (Cayman) Ltd operates through its subsidiaries. It is principally engaged in the time charter service and vessel management services business.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.